Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera | Centers for Disease Control and Prevention |
---|---|
Vaccine adverse event reporting system VAERS | Centers for Disease Control and Prevention |
Interim public health recommendations for vaccinated people.
Use of Pfizer-BioNTech COVID-19 vaccine: Clinical considerations | Centers for Disease Control and Prevention |
---|---|
Moderna COVID-19 vaccine: Fact sheet for recipients and caregivers | Pfizer-BioNTech vaccine: Fact sheet for recipients and caregivers |
Officials discuss COVID-19 vaccine deliveries prioritization criteria.
1FDA for emergency use authorization | Interim considerations for COVID-19 vaccination of healthcare personnel and long-term care facility residents |
---|---|
What to expect after getting a COVID-19 vaccine | Janssen COVID-19 vaccine: Fact sheet for recipients and caregivers |
Centers for Disease Control and Prevention.
4